$312 Million is the total value of Nan Fung Group Holdings Ltd's 28 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NFH | NEW FRONTIER HEALTH CORP | $93,771,000 | +0.5% | 8,350,000 | 0.0% | 30.02% | +3.6% | |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $29,465,000 | +35.8% | 768,708 | 0.0% | 9.43% | +39.9% | |
| KRTX | KARUNA THERAPEUTICS INC | $28,724,000 | +7.3% | 234,811 | 0.0% | 9.20% | +10.6% | |
| EAR | EARGO INC | $19,428,000 | -83.1% | 2,886,724 | 0.0% | 6.22% | -82.6% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $14,762,000 | -18.2% | 1,166,952 | 0.0% | 4.72% | -15.7% | |
| GRTX | GALERA THERAPEUTICS INC | $4,967,000 | -17.6% | 613,223 | 0.0% | 1.59% | -15.1% | |
| NFHWS | NEW FRONTIER HEALTH CORP*w exp 11/30/202 | $4,456,000 | +21.5% | 1,580,000 | 0.0% | 1.43% | +25.2% | |
| NVTA | INVITAE CORP | $4,113,000 | -15.7% | 144,667 | 0.0% | 1.32% | -13.1% | |
| XENE | XENON PHARMACEUTICALS INC | $3,024,000 | -17.9% | 197,880 | 0.0% | 0.97% | -15.5% | |
| EXAS | EXACT SCIENCES CORP | $1,667,000 | -23.2% | 17,464 | 0.0% | 0.53% | -20.9% | |
| OTIC | OTONOMY INC | $1,634,000 | -13.9% | 851,000 | 0.0% | 0.52% | -11.4% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $1,374,000 | -27.1% | 78,720 | 0.0% | 0.44% | -24.9% | |
| EXEL | EXELIXIS INC | $1,357,000 | +16.0% | 64,200 | 0.0% | 0.43% | +19.2% | |
| RUBY | RUBIUS THERAPEUTICS INC | $1,015,000 | -26.8% | 56,768 | 0.0% | 0.32% | -24.6% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $832,000 | -28.9% | 8,265 | 0.0% | 0.27% | -26.9% | |
| SYBX | SYNLOGIC INC | $209,000 | -21.7% | 68,634 | 0.0% | 0.07% | -19.3% | |
| AKRO | AKERO THERAPEUTICS INC | $78,000 | -9.3% | 3,470 | 0.0% | 0.02% | -7.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.